Phoenix Asia Terminates $1B-Scale ACEA Pharma Acquisition After Outside Date
PHOE has more than doubled off its 52-week low of $8.36 on light trading volume (0.2× avg).
Summary
Phoenix Asia terminated its May 4, 2026 agreement to acquire ACEA Pharma for 100,000,000 new shares after the November 2 Outside Date passed without closing. No shares were issued and no consideration was paid, but the deal that was meant to transform the company is off.
Key Events · M&A and Partnerships · PHOE
-
ACEA Pharma Acquisition Terminated
Phoenix Asia delivered written notice on November 3, 2026 terminating the Stock Acquisition Agreement dated May 4, 2026 with ACEA Pharma, Inc. and ACEA Therapeutics, Inc. under Section 11.1(b).
-
Outside Date Passed Without Closing
Closing, which required HSR waiting-period clearance and Nasdaq approval, did not occur on or before the November 2, 2026 Outside Date, triggering the termination right.
-
No Shares Issued, No Cash Paid
The 100,000,000 newly issued ordinary shares contemplated as consideration were never issued, no equity interests of the Target Company were transferred, and no acquisition consideration was paid. The agreement provides for no termination fee.
-
Dispute Risk Flagged
Phoenix Asia reserved all rights and remedies and stated it believes it did not materially breach the agreement; the filing warns the Transferor could dispute the termination or commence litigation.
Analysis · PHOE · Real Estate & Construction
The 100,000,000-share acquisition of ACEA Pharma is dead. Phoenix Asia let the November 2 Outside Date pass and formally terminated on November 3, so the deal that would have reshaped the company will not close. Nothing changed hands — no shares issued, no consideration paid, no termination fee — so the balance sheet is untouched, but the growth story the market was pricing is gone. The company reserved all rights and remedies, and the filing flags the risk that the Transferor disputes the termination or sues. For a company that just reported a $1.2M FY2026 loss on a 4.6% gross margin, losing the transformational transaction leaves it back at square one.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHOE was trading at $18.00 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $388.8M. The 52-week trading range was $8.36 to $133.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.